Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation (MOLTO)

This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter Transformation of CLL.

  • 0 views
  • 21 Feb, 2022
  • 16 locations
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1)

The trial is an open-label, multi-center safety and efficacy trial of epcoritamab in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and Ritcher's Syndrome (RS). The trial consists of two parts, a dose escalation phase (phase Ib) and an expansion phase (phase II).

  • 0 views
  • 30 Jun, 2022
  • 22 locations
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

hepatitis b surface antigen
lymphoma
leukemia
measurable disease
chronic lymphocytic leukemia
  • 33 views
  • 22 Sep, 2022
  • 37 locations
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies

including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as

  • 0 views
  • 23 Sep, 2022
  • 1 location
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, …

platelet count
neutrophil count
etoposide
cyclophosphamide
rituximab
  • 0 views
  • 03 Jan, 2022
  • 1 location
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

This phase I trial studies the best dose and how well copanlisib when given together with nivolumab works in treating patients with Richter's transformation or transformed indolent non-Hodgkin

lymphoma
vincristine
diffuse large b-cell lymphoma
indolent non-hodgkin lymphoma
cancer
  • 17 views
  • 09 Apr, 2022
  • 2 locations
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Richter's syndrome (RS) is a life-threatening complication of chronic lymphocytic leukemia (CLL). It is associated with a switch in histopathology and biology, generally with a transformation of the original CLL clone to diffuse large B-cell lymphoma (DLBCL). The development of RS is accompanied by the onset of B symptoms, rapid …

  • 0 views
  • 15 Dec, 2021
  • 4 locations
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: Venetoclax R-EPOCH: Rituximab Etoposide Prednisone Vincristine Sulfate (Oncovin) Cyclophosphamide Doxorubicin Hydrochloride (Hydroxydaunomycin) R-CHOP: Rituximab Cyclophosphamide Vincristine …

  • 16 views
  • 25 Jul, 2022
  • 2 locations
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

  • 1 views
  • 28 Feb, 2022
  • 12 locations
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

gilbert's syndrome
b-cell lymphoma
lymphoma
neutrophil count
venetoclax
  • 21 views
  • 23 Jul, 2022
  • 7 locations